Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
P/B ratio for Intensity Therapeutics, Inc. (INTS)
P/B ratio as of 2023: 5.61
According to Intensity Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.61. At the end of 2022 the company had a P/B ratio of -5.17.
P/B ratio history for Intensity Therapeutics, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 5.61 |
| 2022 | -5.17 |
| 2021 | -8.99 |
| 2020 | -50.10 |
| 2019 | -32.86 |